Caricamento...
Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites
Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM(197)). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal...
Salvato in:
| Pubblicato in: | Sci Rep |
|---|---|
| Autori principali: | , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4740906/ https://ncbi.nlm.nih.gov/pubmed/26841683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep20488 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|